logo

Aridis Pharmaceuticals Inc (ARDS)



Trade ARDS now with
  Date
  Headline
8/12/2021 9:05:57 AM Aridis Pharma Q2 Net Loss $5.5 Mln Or $0.49/shr Vs. Net Loss $4.2 Mln Or $0.47/shr Prior Year
8/2/2021 8:10:11 AM Aridis Pharma Announces $25 Mln Registered Direct Offering Priced At A Premium To Market
7/19/2021 8:32:01 AM Aridis Announces License Of Suvratoxumab, Phase 3-Ready Monoclonal Antibody, From AstraZeneca
2/23/2021 5:51:35 AM Aridis Pharma Augments Inhaled AR-711 MAb To COVID-19 With A Second MAb AR-713 To Neutralize COVID-19 Mutated Variants
11/20/2020 4:22:27 PM Aridis Pharmaceuticals Q3 Loss/share $0.65 Vs. Loss $0.87 Year Ago
10/14/2020 5:33:56 AM Aridis Pharmaceuticals Plans $8.5 Mln Registered Direct Offering
9/8/2020 5:39:37 AM Aridis Reaches Agreement With FDA To Simplify AR-501 Phase 2 Trial Design
6/22/2020 5:34:21 AM Aridis Announces Positive Results From Phase 1 Portion Of Phase 1/2a Clinical Trial Of AR-501
6/15/2020 5:36:01 AM Aridis Pharmaceuticals Appoints Hasan Jafri As Chief Medical Officer
5/4/2020 5:47:27 AM Aridis Pharma Enrolls First COVID-19 Patient In Ongoing Phase 3 AR-301 Clinical Trial In Ventilator Associated Pneumonia
4/8/2020 5:04:51 PM Aridis Pharmaceuticals Q4 Loss/share $0.63 Vs. Loss $0.67 Year Ago